455 Mission Bay Boulevard South
Tel: 415-482-5300, Toll Free 855-482-NKTR (6587)
About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates.
Stock Symbol: NKTR
Stock Exchange: NASDAQ
350 articles with Nektar Therapeutics
First-in-Human Data Presented from Phase 1a Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology
Nektar Therapeutics announced the results of the first-in-human Phase 1a study evaluating single-ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator in clinical development for the treatment of autoimmune and other chronic inflammatory conditions.
Nektar Therapeutics to Host Webcast Conference Call with Immunology Expert for Analysts & Investors During 2019 European Congress of Rheumatology (EULAR 2019)
Nektar Therapeutics announced that it will webcast an analyst and investor conference call with an immunology expert and company management on Thursday, June 13, 2019 at 8:00 a.m. EDT during EULAR 2019.
According to a BioSpace survey, almost 70% of respondents are likely to look for a new job in the 12 months. The question is, why? Of those planning to look for a new job, 54% said they wanted new challenges and 42% said they wanted more rewarding opportunities. How about you? Are you ready to lo...
Nektar Therapeutics Presents Biomarker and Clinical Data from PIVOT-02 Phase 2 Study of Bempegaldesleukin with Nivolumab at 2019 ASCO Annual Meeting
Nektar Therapeutics announced that biomarker and clinical data from PIVOT-02 is being presented at the 2019 American Society of Clinical Oncology Meeting in Chicago, Illinois.
Inheris Biopharma was formed as Nektar awaits the FDA approval of a pain medication that does not have the euphoric side effects of other opioids.
Trovagene Announces Research Collaboration with Nektar Therapeutics to Evaluate Efficacy of the Combination of Onvansertib and ONZEALD™ in Models of Colorectal Cancer
ONZEALD is currently being evaluated in a Phase 3 trial in patients with metastatic breast cancer and brain metastases
Nektar Therapeutics announced the formation of Inheris Biopharma, Inc., a wholly-owned subsidiary of Nektar and a CNS-focused company.
Nektar Therapeutics Announces Five Accepted Abstracts at 2019 American Society of Clinical Oncology's (ASCO) Annual Meeting
Nektar Therapeutics announced five abstracts accepted for presentation at the 55th Annual Meeting of the American Society of Clinical Oncology, which is being held from May 31 to June 4, 2019 at the McCormick Place Convention Center in Chicago, Illinois.
Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2019.
Nektar to Announce Financial Results for the First Quarter 2019 on Wednesday, May 8, 2019, After Close of U.S.-Based Financial Markets
Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Daylight Time/2:00 p.m. Pacific Daylight Time.
According to a recent BioSpace survey, 93% of respondents are open to a new job for the right opportunity. Are you one of the 93%? If so, keep your eyes open for those opportunities and don't stop looking. You never know what may come your way!
Here’s a look at six San Francisco Bay Area life science companies that have hit a variety of “best of” lists recently, in no particular order.
The San Francisco Business Times came out with a list of 64 major Bay Area employers and their median pay, which they then compared to their chief executives’ annual compensation.
Nektar Therapeutics Presents Preclinical Data on its Immuno-Oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019
Nektar Therapeutics presented preclinical data on its immuno-oncology pipeline candidates, bempegaldesleukin, a CD122-preferential IL-2 pathway agonist, and NKTR-255, an IL-15 receptor agonist, at the American Association for Cancer Research Annual Meeting 2019.
Vaccibody AS and Nektar Therapeutics Present New Preclinical Data from their Immuno-Oncology Collaboration at the American Association for Cancer Research (AACR) Annual Meeting 2019
Vaccibody AS and Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of new preclinical data for VB10.NEO, a personalized neoantigen cancer vaccine, combined with bempegaldesleukin (NKTR-214 or bempeg), a CD122-preferential IL-2 pathway agonist
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
Nektar Therapeutics to Webcast Presentation at the Cowen and Company 39th Annual Health Care Conference
Nektar Therapeutics announced that its Chief Scientific Officer, Jonathan Zalevsky, Ph.D., is scheduled to present at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019 at 9:20 a.m. Eastern Time.
According to a recent BioSpace survey, 70% of life science employers indicated their company anticipates an increase in the number of open positions during 2019. So if you are on the job hunt, keep your eye out for new positions posted throughout the year!
BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced the addition of Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the USA and Canada, and Pfizer Inc. (NYSE: PFE) to its Nektar Therapeutics (Nasdaq: NKTR) clinical collaboration to evaluate a novel triple combination therapy in pancreatic cancer.
Nektar Therapeutics Presents Preliminary Immune Activation, Safety and Clinical Activity Data from the Ongoing Dose-Escalation Stage of the REVEAL Study at 2019 ASCO-SITC Meeting
Nektar Therapeutics announced early results from the ongoing dose-escalation stage of the first-in-human REVEAL Phase 1/2 clinical study evaluating the safety and efficacy of NKTR-262, a novel toll-like receptor 7/8 agonist, in combination with bempegaldesleukin*, a CD122-preferential IL-2 pathway agonist.